No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

NCT02421120Phase 4Completed21 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies.

Chi Yulong, Xu Juan, Bai Nan et al. · Expert Rev Anti Infect Ther · 2023

PMID: 36629486Meta-Analysis

A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections.

Saeed Muhammad Waqas, Gillani Syed Wasif, Mahmood Rana Kamran et al. · Biomed Res Int · 2022

PMID: 35978637Meta-AnalysisFull text (PMC)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR).

Khankhel Z S, Dillon R J, Thosar M et al. · Ann Clin Microbiol Antimicrob · 2022

PMID: 36192782Meta-AnalysisFull text (PMC)

Real-world use of ceftolozane/tazobactam: a systematic literature review.

Puzniak Laura, Dillon Ryan, Palmer Thomas et al. · Antimicrob Resist Infect Control · 2021

PMID: 33832545Meta-AnalysisFull text (PMC)

Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.

Maraolo Alberto Enrico, Mazzitelli Maria, Trecarichi Enrico Maria et al. · Int J Antimicrob Agents · 2020

PMID: 31923569Meta-Analysis

The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-A meta-analysis of randomized controlled trials.

Cheng I-Ling, Chen Yu-Hung, Lai Chih-Cheng et al. · Int J Antimicrob Agents · 2020

PMID: 31786332Meta-Analysis

Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.

Roilides Emmanuel, Ashouri Negar, Bradley John S et al. · Pediatr Infect Dis J · 2023

PMID: 36689671RCTFull text (PMC)

Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.

Jackson Carl-Christian A, Newland Jason, Dementieva Nataliia et al. · Pediatr Infect Dis J · 2023

PMID: 37000942RCTFull text (PMC)

Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.

Kullar Ravina, Wagenlehner Florian M, Popejoy Myra W et al. · J Antimicrob Chemother · 2017

PMID: 27999024RCT

Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

Miller Benjamin, Hershberger Ellie, Benziger David et al. · Antimicrob Agents Chemother · 2012

PMID: 22450972RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Ceftolozane (substance)
SNOMED CT: 708792003
UMLS CUI: C3852726
RxNorm CUI: 1597609

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.